Patents

US 12612409 B2: Pyrrolopyrimidines as CFTR potentiators

Granted
2026-04-28
Filed
2023-04-13 application 18134455
Type
Utility · 20 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Source: PTBLXML, file of 2026-04-28 (ipgb20260428.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Cystic Fibrosis Foundation 4 patentsUS company or organizationBethesda, MDCYSTIC FIBROSIS FOUNDATION Nonprofit EXACT high confidence: identical full name and statePTBLXML, file of 2026-04-28

Inventors

InventorPlacePatentsPerson pageSource
Joseph Walter StrohbachWentzville, MO25PTBLXML, file of 2026-04-28
David Christopher LimburgSalem, CT8PTBLXML, file of 2026-04-28
John Paul MathiasConcord, MA17PTBLXML, file of 2026-04-28
Atli ThorarensenStow, MA21PTBLXML, file of 2026-04-28
Rajiah Aldrin DennySharon, MA8PTBLXML, file of 2026-04-28
Christoph Wolfgang ZapfOakland, CA24PTBLXML, file of 2026-04-28
Daniel ElbaumNewman, MA26PTBLXML, file of 2026-04-28
Lori Krim GavrinVillanova, PA12PTBLXML, file of 2026-04-28
Ivan Viktorovich EfremovChestnut, MA32PTBLXML, file of 2026-04-28

CPC categories

SubclassCategoryFirst groupSource
C07DHeterocyclic compoundsC07D487/04PTBLXML, file of 2026-04-28
A61KPreparations for medical, dental or toiletry purposesA61K31/519PTBLXML, file of 2026-04-28
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P11/12PTBLXML, file of 2026-04-28

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2024-09-05Assignment
Assignment of assignor's interest
PFIZER INC. signed 2017-10-04CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. BETHESDA, MD68492/606PASDL, file of 2026-10-15
2024-09-05Assignment
Assignment of assignor's interest
STROHBACH, JOSEPH WALTER signed 2017-07-19
LIMBURG, DAVID CHRISTOPHER signed 2017-08-22
MATHIAS, JOHN PAUL signed 2017-07-19
THORARENSEN, ATLI signed 2017-07-21
DENNY, RAJIAH ALDRIN signed 2017-07-20
ZAPF, CHRISTOPH WOLFGANG signed 2017-08-01
ELBAUM, DANIEL signed 2017-07-18
GAVRIN, LORI KRIM signed 2017-07-24
EFREMOV, IVAN VIKTOROVICH signed 2017-08-08
PFIZER INC. NEW YORK, NY68492/592PASDL, file of 2026-10-15
2024-09-05Assignment
Assignment of assignor's interest
CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. signed 2019-05-29CYSTIC FIBROSIS FOUNDATION BETHESDA, MD68492/586PASDL, file of 2026-10-15

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.